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Abstract: A novel SARS-like illness called Middle East respiratory syndrome coronavirus (MERS-CoV), caused by an emerging
coronavirus, has been a recent cause for concern due to its fatality and pandemic potential. Developing a peptide-based vaccine could be
helpful in fighting against the virus. Since the experimental procedure is time-consuming and expensive, computational analysis can play
an important role in accelerating the process. Therefore, the aim of this study was to computationally identify cytotoxic T-lymphocyte
epitopes presented by the human leukocyte antigen (HLA)-A*0201, as this is the most frequent HLA class I allele among Middle Eastern
populations. The receptor-binding domain of the spike glycoprotein of MERS-CoV, by which the virus binds to its entry receptor to
further infect host cells, is a potential candidate used here for running our in silico epitope identification process. The results include
predicted epitopes together with their interaction properties with major histocompatibility complex (MHC) molecules and also the
binding behavior of MHC–epitope complexes to human T-cell receptor. Predicted epitopes with the most preferable binding properties
are beneficial for vaccine development. Therefore, the huge experimental workload for epitope-based vaccine design will be minimized.
Key words: Middle East respiratory syndrome coronavirus, cytotoxic T-lymphocyte epitopes, HLA-A2, computational prediction,
vaccine design

1. Introduction
Middle East respiratory syndrome coronavirus (MERSCoV), which was called human coronavirus EMC (hCoVEMC) before (Zaki et al., 2012), was first isolated from
the sputum of a patient with acute pneumonia and renal
failure in Jeddah, Saudi Arabia, in September 2012. By 17
July 2013, the World Health Organization had confirmed
82 cases of infection, including 45 deaths, mostly from the
Arabian Peninsula (Saudi Arabia, Qatar, Jordan, and the
United Arab Emirates).
Like severe acute respiratory syndrome coronavirus
(SARAS-CoV), MERS-CoV is also a beta-coronavirus that
originated from bats and causes pulmonary illness. The
spike (S) protein of the virus is responsible for mediating
the infection by binding to its entry receptor, which
has been identified as CD26 (also known as dipeptidyl
peptidase 4, DPP4) (Raj et al., 2013). The MERS-CoV S
protein is a membrane glycoprotein with 1353 amino
acids, including a domain at the N-terminal region (S1),
a membrane-proximal domain (S2), a transmembrane
domain, and an intracellular domain. The determinant
part by which the virus targets its biologic receptor is
located in the S1 domain (Wang et al., 2013), called the
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receptor-binding domain (RBD), which was determined to
be a fragment of 231 amino acids (residues 358 to 588) (Mou
et al., 2013).
Obviously, the RBD is a crucial part to be further
studied for vaccine development and drug design in order to
stimulate the immune system against the virus or to inhibit its
interaction with its receptor, respectively. Prior experience in
SARS-CoV vaccine development would suggest that vaccine
candidates designed on the basis of the RBD subunit of the
SARS-CoV S protein (located in the S2 subunit) are more
effective in comparison with vaccines based on DNA or an
inactivated virus (He et al., 2005; Du et al., 2009; Jiang et al.,
2012; Lu et al., 2013). Therefore, in the case of MERS-CoV,
searching for similar peptide vaccines seems to be effective.
Moreover, in novel strategies for vaccine design process such
as the use of epitope-loaded dendritic cells (Hatipoğlu et al.,
2013), the exact identification of important antigenic sites of
a protein is undoubtedly needed. Experimental screening of
specific major histocompatibility complex (MHC)-binding
peptides is expensive and time-consuming, as it requires
a binding assay for each single peptide; by performing a
reliable in silico analysis, we can summarize the steps for a
MERS-CoV vaccine development procedure.
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Cytotoxic T lymphocytes (CTL)-mediated cellular
immunity is the most important mechanism in controlling
viral infections (Wodarz and Nowak, 2000). This type of
immunity is mediated by MHC class I CTLs: restricted
CD8+ CTLs. MHC class I CTLs have short epitopes
(usually about 9 residues) from proteolytically cleaved
proteins to CTLs; however, statistics say that only 1 CTL
epitope out of 200 nanomer epitopes will be able to bind
to a specific MHC (Lundegaard et al., 2006). On the other
hand, MHCs are very polymorphic, though only some of
their alleles may become frequent in a given population.
What we present in this study is based on 3 steps.
First, the CTL nanomer epitopes from the MERS-CoV
receptor-binding domain of its S protein were obtained
using the best 3 of all epitope prediction servers available
on the World Wide Web. Once the specific epitopes
were identified, the next step was to examine whether
the predicted epitopes could bind efficiently to the most
frequent MHC class I allele in Middle Eastern populations,
which is HLA-A*0201 (Sheth et al., 1985; Valluei et al.,
2005; Ferrante and Gorski, 2007). Finally, epitope-loaded
MHC class I molecule interactions with human T-cell
receptor (TCR) α and β were modeled. The latter 2 steps
were done using an in silico molecular docking technique.
2. Materials and methods
2.1. Retrieval of target amino acid sequence
The amino acid sequence of the S glycoprotein of MERSCoV was obtained from the NCBI protein database
(accession number AGN52936.1). The receptor-binding
domain (residues 358–588) was highlighted for further
analysis.
2.2. CTL epitope prediction and modeling
CTL-specific epitope prediction was performed using
NetCTL 1.2 (Larsen et al., 2007), EpiJen (Doytchinova et
al., 2006), and NHLApred (Bhasin and Raghava, 2007).
NHLApred and EpiJen expanded the MHC class I binding
prediction to different MHC alleles, making it possible to
specify a favored MHC allele from the existing list of HLA
alleles. Here, the HLA allele selected for the prediction
was HLA-A*0201. However, the NetCTL server predicts
its MHC class I binding peptides for different supertypes;
as a result, NetCTL selected the HLA-A2 supertype.
Having obtained the predicted epitopes from the
servers, their 3D structures were modeled using the
PEPstr server (Kaur et al., 2007), which models the tertiary
structure of peptides (7 to 25 amino acids long) with high
accuracy.
2.3. MHC and TCR model retrieval and molecular
docking
The structure of a complex between HLA-A*0201 and
TCRαβ was fetched from the Protein Database Bank (PDB
ID: 1AO7) and used as our reference structure.

A molecular docking technique using ClusPro server
(Comeau et al., 2004a, 2004b; Kozakov et al., 2010)
was then performed to model the interactions of the
3D-modeled epitopes with MHC and also to model the
interactions of epitope–MHC with the TCR molecule. We
first docked the peptidic epitopes into the reference MHC
molecule. After identifying the most appropriate peptide–
MHC complex for each epitope, it was separately docked
into TCRα and TCRβ.
3. Results and discussion
A protective high-affinity epitope binds the MHC molecule
with enough strength and in a near-native binding
orientation. The resulting epitope–MHC complex should
bind the TCR molecule in the same manner. Therefore,
since not every peptide with high affinity to MHC proteins
is considered an epitope, it is better to make sure that the
predicted epitopes can efficiently interact with MHC and
TCR molecules.
3.1. CTL epitope prediction and modeling
In this study, 3 CTL epitope prediction servers were
employed to construct an in silico approach to identify the
HLA-A*0201-restricted T-cell epitopes for MERS-CoV.
Each server uses a different algorithm, guaranteeing that
nearly all possible epitopes would be predicted.
In NetCTL 1.2, the MHC peptide binding and
the proteasome cleavage events are predicted using
artificial neural networks (ANNs). NetCTL 1.2 also
makes predictions about TAP transport efficiency
via a weight matrix method proposed by Peters et al.
(2003). In NHLApred, the CTL epitopes are predicted
with a combinatorial approach consisting of ANNs and
quantitative matrices (QMs) (Bhasin and Raghava, 2007),
and the EpiJen server implements a QM method to predict
CTL epitopes (Doytchinova et al., 2006). Six T-cell epitopes
were identified by these prediction algorithms and are
shown in Table 1. The number of predicted epitopes may
seem low, but it is important to bear in mind that we
studied the receptor-binding domain of the S glycoprotein,
which is a fragment only 231 amino acids in length.
There is a further more subtle point that we must
consider, which is that the epitope should not be hidden by
glycosylation. Among all experimentally validated human
CTLs, only a small number of them are shown to be
glycosylated (whether N- or O-glycosylated) (Szabó et al.,
2009); however, there is experimental evidence that shows
that glycosylation might deactivate the peptidic T-cell
epitope (Lisowska, 2002; Szabó et al., 2009). Therefore,
predicted epitopes were checked to see if their residues
were glycosylated. Using UniProt, it was shown that the
only glycosylated residue in the receptor-binding domain
of the MERS-CoV spike is an asparagine, which is not
located in any of predicted epitopes (Magrane, 2011).
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Table 1. Peptides predicted, via epitope prediction methods,
as HLA-A2/A*0201-restricted T-cell epitopes of the receptorbinding domain of MERS-CoV spike protein.
Peptide

Sequence

Prediction methods

P1

LLSGTPPQV

NetCTL, EpiJen

P2

ILDYFSYPL

NetCTL, EpiJen

P3

ILATVPHNL

NetCTL, EpiJen

P4

NLTTITKPL

EpiJen

P5

LQMGFGITV

NetCTL, EpiJen

P6

FSNPTCLIL

NHLApred

Using the PEPster server, tertiary structures of the
peptides were modeled. With this server, models can
be generated under different modeling conditions, such
as vacuum, hydrophobic, or hydrophilic environment
simulations. Here, hydrophilic conditions were selected
due to the fact that not only are epitopes in a hydrophilic
environment while binding to MHC molecules, but there
are also water molecules located in the MHC groove to
stabilize the peptide–MHC interaction. The server gives one
model for each short peptide in PDB format. The modeling
algorithm is concerning with β-turns, which are the most
important counterpart in short peptides, in addition to
regular structures (Kaur et al., 2007).
3.2. Molecular docking
Docking of each predicted epitope into a HLA-A*0201
molecule, obtained from the PDB (PDB ID: 1AO7), was
done using ClusPro. It provides different docking options
and, if we have the knowledge of what forces dominate in our
complex, it is possible to choose from these options. Since
the major interaction between an immunogenic peptide
and MHC is hydrophobic force (Ferrante and Gorski, 2007),
models were created under hydrophobic conditions. The
server’s output contained at least 6 different results for each

peptide. Among these docked models, conformations with
high similarity to the native complex of 1AO7 were selected.
The considerations included: 1) whether the peptide is
docked into the peptide binding groove of MHC in a way such
that the whole peptide is completely located into the groove,
2) whether the distance between the peptide and groove is
comparable to that of the native structure, and 3) whether
the C-terminal residue of the peptide has interaction with
the groove. The latter consideration is because in MHC class
I restricted CTL epitopes, the anchoring residue is often the
residue located in the peptide’s C-terminal. After choosing
well-oriented peptide–MHC complexes (the closest ones to
the native structure 1AO7) from the 6 models, their binding
free energy scores (generated by the ClusPro server itself)
were compared and the peptide–MHC complex with the
lowest score was selected for further analysis. However, it
was the orientation factor that played the most important
role in our investigations. The binding free energy score
only came into consideration when there were negligible
differences between well-oriented models. This process was
done for each previously predicted epitope.
The selected peptide–MHC complex was docked into
TCRα and TCRβ separately. In this case, models created
with the “balanced” mode of ClusPro were extracted and
analyzed, as there is a combination of chemical forces
participating in the interaction between the peptide–MHC
and TCR molecule, not just one. Here, native TCR-binding
orientation over peptide–MHC class I is a way that TCRβ
binds from its N-terminal domain; for TCRα, it binds from
where the first N-terminal residue is located in its single
domain. The peptide–MHC/TCR complex with the lowest
binding free energy was selected among the well-oriented
coordinates. This is the same scenario previously done for
selecting the best peptide–MHC complex.
Molecular docking results are prepared in Table 2.
Finally, the predicted epitopes’ potential to be the
true epitopes was evaluated on the basis of their docking

Table 2. Molecular docking results of predicted epitopes.
Peptide/MHC
Peptide

Orientation scorea

Binding free energy score

Real epitope
potential

Orientation score a

Binding free
energy score

TCRα

TCRβ

TCRα

TCRβ

P1

+

–971

+

+

–601

–916

High

P2

+

–1286

+/-

+/-

–679

–971

Medium

P3

+

–1394

+/-

+/-

–635

–762

Medium

P4

+

–1009

-

-

–623

–778

Low

P5

+

–1338

+

+/-

–685

–855

Medium

P6

++

–1389

+/-

+

–636

–910

High

a
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Peptide-MHC / TCRαβ

++: certifiable, +:acceptable, +/-: intermediate, -:false.
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properties. Peptides with binding orientations closer to the
native structure and lower binding free energy scores are
ranked higher in having the potential to be real epitopes.
Among the 6 predicted epitopes, it was concluded
that 2 of them (P1 and P6) have the potential to be real
epitopes, as their binding orientations in interaction with
either TCRαβ or HLA-A*0201 molecules were close to the
reference coordinate and their binding free energies were
the lowest scores among all binding scores. Among the
predicted epitopes, P4 seemed to have low potential to be a
real epitope, demonstrating that not all predicted epitopes
have the potential to be real ones.
In conclusion, the combination of epitope prediction
processes and a knowledge-based molecular docking
technique can provide a more reliable identification of
MHC class I CTL epitopes compared to merely using
automated epitope-predicted servers. Therefore, this study
was conducted to predict HLA-A*0201-restricted CTL
epitopes of the receptor-binding domain of MERS-CoV S
protein in a more reliable way. Results revealed possible
CTL epitopes and further computational analysis revealed
their real epitope potential.

Since bioinformatic tools are growing quickly in both
technique and number, they have become a crucial part
of different biological analyses, such as drug design, drug
discovery, and the vaccine design process (Öztürk, 2013).
Although computational studies are not as accurate as
experimental assays, by making use of bioinformatics tools
we can improve the output results of experimental assays
by adding complementary steps based on our theoretical
knowledge.
The combinatorial approach used here can improve
the process of epitope prediction compared to the
conventional methods. Such in silico approaches can
dramatically reduce the number of peptides necessary
for further experimental screenings. Therefore, this study
was conducted to predict HLA-A*0201-restricted CTL
epitopes of the receptor-binding domain of MERS-CoV
S protein with a new, improved method. The results can
suggest the best epitope candidates to be further tested
experimentally in vaccine designing procedures.
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